What you need to know about alanines and the risk of dementia

The benefits of alpha-lactalbumin are well known.

Alpha-lactic acid, a naturally occurring acid in foods, has been linked to heart health and can help prevent type 2 diabetes and heart disease.

But studies have also linked alanins to heart disease and stroke.

Now, researchers at the University of Minnesota are looking at how alanin may be linked to Alzheimer’s disease.

Researchers from the Mayo Clinic and the University Health Network analyzed data from more than 7,000 people with dementia from the Framingham Heart Study, which was designed to identify people at higher risk for developing the disease.

They looked at people who were categorized as being on the high risk group, those who were diagnosed with Alzheimer’s or dementia at least six years before the onset of the disease, and people who had other risk factors.

They found that those on high risk for Alzheimer’s were also more likely to have a genetic predisposition to the disease and have higher levels of alpha lactalbumins in their blood.

“It’s not really clear how the association with alpha lactic acid is related to Alzheimer,” said Dr. Mark Wojcik, associate professor in the Mayo Center for the Study of Aging and lead author of the study.

“It’s a combination of genetic and environmental factors.

That could be a genetic difference, a genetic abnormality, or it could be something that has a direct impact on the health of the person.”

Alanins in food, such as alanes and galactans, are naturally occurring in foods.

When we eat these foods, we absorb these acids from the food and the resulting chemical reactions in the body cause the release of a chemical called alpha-amylase, which breaks down the protein.

This process is linked to the production of beta-amino acids in the brain.

Alpha lactamates also have an effect on the immune system, as they may promote inflammation.

The researchers found that when people with Alzheimer�s disease were compared to people who did not have the disease they were more likely than those who did to have elevated levels of these alpha lacase-producing alanases in their bodies.

Alpha alpha-galactamate levels in the blood of people on the low risk group were also found to be higher than those of those on the highest risk group.

The researchers believe that, at least in part, this is due to a genetic variation that may be affecting the immune response in the brains of people with the disease compared to those without the disease; this could be one factor in why people with early dementia have a lower immune response.

The study will be published in the April issue of Neurology.